Glatiramer Acetate Complexes CpG Oligodeoxynucleotides into Nanoparticles and Boosts Their TLR9-Driven Immunity
- 1 November 2024
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 21 (12) , 6323-6338
Abstract
Unmethylated cytosine-guanine oligodeoxynucleotides (CpG ODNs) have a storied history as agonists for Toll-like receptor 9 (TLR9). CpG ODNs have shown promising antitumor effects in preclinical studies by inducing potent proinflammatory immune responses. However, clinical success has been hindered by inconsistent efficacy and immune-related toxicities caused by systemic exposure to CpG ODNs. We previously identified that glatiramer acetate (GA), an FDA-approved, lysine-rich polypeptide, could complex class B CpG into cationic nanoparticles which persist at the intratumoral injection site while mitigating the induction of systemic proinflammatory cytokines in mouse tumor models. To extend GA applications across subtypes of CpG ODN (class A, B, and C), we evaluated physiochemical properties and identified the immunological signaling of GA and its complexes with different classes of CpG ODNs. We compared the physiochemical characteristics of three types of GA-CpG nanoparticles, followed by assessments of cell uptake efficiency and endolysosomal trafficking. We then performed successive in vitro and in vivo assays to evaluate immunological discrepancies. Complexation with GA preserved the immunological activity of CpG ODN subtypes while encapsulating them into cationic spherical nanoparticles. GA improved the cellular uptake of CpG ODNs, generally increased retention in early endosomes, and amplified immunological responses. A subsequent in vivo experiment confirmed the achievement of potent tumor suppression while mitigating systemic immune-related toxicities. Together, these data help elucidate the noncanonical role of GA to serve as a nucleic acid delivery scaffold that can improve the efficacy and safety of CpG adjuvant for clinical cancer immunotherapy.Keywords
Funding Information
- Small Business Technology Transfer (R41CA272024)
This publication has 65 references indexed in Scilit:
- Camptothecin-loaded mesoporous silica nanoparticles functionalized with CpG oligodeoxynucleotide as a new approach for skin cancer treatmentInternational Journal of Pharmaceutics, 2024
- Type I interferon-mediated tumor immunity and its role in immunotherapyCellular and Molecular Life Sciences, 2022
- Emerging vaccine nanotechnology: From defense against infection to sniping cancerActa Pharmaceutica Sinica B, 2022
- Nanotechnology-empowered vaccine delivery for enhancing CD8+ T cells-mediated cellular immunityAdvanced Drug Delivery Reviews, 2021
- Glatiramer acetate enhances tumor retention and innate activation of immunostimulantsInternational Journal of Pharmaceutics, 2021
- Constructing a Biomaterial to Simulate Extracellular Drug Transport in Solid TumorsMacromolecular Bioscience, 2020
- Glatiramer acetate persists at the injection site and draining lymph nodes via electrostatically-induced aggregationJournal of Controlled Release, 2019
- Cytotoxicity of polycations: Relationship of molecular weight and the hydrolytic theory of the mechanism of toxicityInternational Journal of Pharmaceutics, 2017
- Effect of pH on the Behavior of Hyaluronic Acid in Dilute and Semidilute Aqueous SolutionsMacromolecular Symposia, 2008
- Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activitiesEuropean Journal of Immunology, 2003